Navigation Links
Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Date:12/6/2008

ickle cell disease.

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: IndividualPatient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group [LBA-6]

Julia Bohlius, M.D., MScPH, University of Bern, Bern, Switzerland

*Abstract LBA-6 is being presented on Saturday, December 6, at 2:00 p.m. at the ASH press conference on treatment advances in leukemia and lymphoma. The embargo for this abstract will break at that time.

Results of this first large-scale study examining how survival rates are affected by the use of erythropoiesis-stimulating agents (ESAs) for the treatment of anemia in patients with cancer showed that ESAs increased on-study mortality and worsened overall survival, confirming previous studies that have suggested that ESAs may negatively affect the overall health of these patients.

In order to assess the effect of ESAs on mortality, a meta-analysis was conducted of 13,933 patients with cancer enrolled in 53 randomized, controlled clinical trials comparing epoetin alfa, epoetin beta, and darbepoetin alfa plus red blood cell transfusions versus red blood cell transfusions alone for the prevention or treatment of anemia during or after receiving anticancer therapy. Thirty-eight of these trials, which included 10,441 patients, used chemotherapy as the anticancer regimen.

The primary endpoints of the study were on-study mortality and overall survival in patients with cancer receiving chemotherapy, including all studies where more than 70 percent of patients enrolled received chemotherapy, and all patients with cancer regardless of the type of anticancer therapy. On-study mortality was defined as death from any cause between the date of being randomized in the clinical trial and 28 days following the end of the treatment phase of the study. Overall
'/>"/>

SOURCE American Society of Hematology
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. University of Kansas Medical Center to Deploy Velos eResearch System-Wide
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Dominos Pizza Pledges Support to the Fifth Annual St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign
7. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
8. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
9. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
10. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
11. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013   Accuray ... today the publication of study results involving hundreds ... Robotic Radiosurgery System, the most widely used form ... study followed 304 patients for a median of ... and found that 97 percent of patients with ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... point-of-care blood analysis systems, announced today that ... present at the Stifel Annual Dental & Veterinary Conference ... The conference will be held at Le Parker Meridien ... About Abaxis Abaxis develops, manufactures, ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... 2012  PAREXEL International Corporation (NASDAQ: PRXL ) will ... 2012 on Monday, January 30, 2012 after the close of ... website at www.PAREXEL.com and on the PR Newswire ... a conference call and live webcast at 10:00 a.m. ET ...
... 2012 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... application for BMN-111, an analog of C-type Natriuretic Peptide ... initiate the Phase 1 trial in the first quarter ... moderately and severely affected animal models and has been ...
Cached Medicine Technology:PAREXEL Announces Date of Second Quarter Fiscal Year 2012 Earnings Release and Conference Call 2BioMarin Announces IND for BMN-111 for Achondroplasia is Active 2BioMarin Announces IND for BMN-111 for Achondroplasia is Active 3BioMarin Announces IND for BMN-111 for Achondroplasia is Active 4
(Date:5/21/2013)... Long Beach, CA (PRWEB) May 21, 2013 ... the 3rd Annual EB-5 Investment Summit: Dealmakers Conference ... The Dealmakers Conference will focus on exploring alternative ... will provide the latest market, legal and economic ... executives, immigration and legal professionals within the EB-5 ...
(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The ... on cable networks and cable channels across the country, ... on its YouTube channel. The producers of the series ... in the shipping industry, the manufacturing industry, health-related companies, ... medical facilities and medical practitioners in all parts of ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving ... residents in the Creative Corridor region, is releasing results ... news conference on Thursday, May 23rd at 10:30 a.m. ... 2008. , The survey is a critical ... efforts that attract, nurture and retain people of diverse ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... as patient engagement, physician communication, and staff coordination may ... patient survival rates than others, according to a study ... Journal of the American Society of Nephrology (CJASN). ... figure out what top-performing dialysis units might be doing ...
... will receive a $2.3 million New Innovator Award today ... platelets and the technology that makes them work. ... to build platelets of biodegradable polymers, which link with ... and fellow researchers initially pursued the technology after seeing ...
... (BMC) has been awarded a four year, $5.7 million ... (NHLBI) for investigators from Boston University School of Medicine ... Cardiovascular Outcomes and Disparities. The goal of the Center ... health reform on cardiovascular (CV) care and outcomes, and ...
... Gardner HealthDay Reporter , WEDNESDAY, Sept. 29 (HealthDay ... younger women finds that screening can lower the risk of ... The study, done in Sweden, found that women who were ... 1,250 women five times over a 10-year period would save ...
... Kang Zhang, MD, PhD, professor of ophthalmology at the ... director of UCSD,s Institute of Genomic Medicine, has been ... Zhang and co-principal investigators Sheng Ding, PhD, from ... the University of Washington, received the highest possible scores ...
... of immunotherapy to children with neuroblastoma, a nervous system ... and free of disease progression after two years, according ... School of Medicine and fellow institutions. The percentage rose ... to 66 percent for children receiving immunotherapy plus standard ...
Cached Medicine News:Health News:Why do some dialysis centers have higher survival rates? 2Health News:Researchers to study effects of Mass. health reform 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 3Health News:UCSD receives NIH Transformative R01 Award for stimulation of neuron regeneration in the retina 2Health News:UCSD receives NIH Transformative R01 Award for stimulation of neuron regeneration in the retina 3Health News:Addition of immunotherapy boosts pediatric cancer survival in children with neuroblastoma 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: